There are 3397 resources available
Virtual nursing services: Data for healthier patient lives
Presenter: Helena Ullgren
Session: How does digitalisation help personalised care throughout the patient journey?
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered paper session - Haematological malignancies
Resources:
Webcast
1184MO - Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)
Presenter: Marianne Pavel
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Q&A and Discussion
Presenter: All Speakers
Session: ESMO Guideline updates on supportive and palliative care
Resources:
Slides
Webcast
LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial
Presenter: Mary McCormack
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
1185MO - Activity and safety of avelumab alone or in combination with cabozantinib in patients with advanced high grade neuroendocrine neoplasias (NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter AVENEC and CABOAVENEC trials
Presenter: Matthias M. Weber
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
824O - Treatment and survival in patients with localized primary ocular adnexal MALT lymphoma: A large bicentric cohort study
Presenter: Lin-rui Gao
Session: Proffered paper session - Haematological malignancies
Resources:
Abstract
Slides
Webcast
New technologies in hospitals, improving patient experience
Presenter: Ligia Kornowska
Session: How does digitalisation help personalised care throughout the patient journey?
Resources:
Slides
Webcast
LBA9 - innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Presenter: Ignace Vergote
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
725MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas
Presenter: Valentina Gambardella
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast